Screener
BridgeBio Pharma BBIO Total costs & expenses
Total costs & expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 126,636 | 111,431 |
| Selling, general and administrative | 163,896 | 106,365 |
| Restructuring, impairment, and related charges | — | 570 |
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's total costs & expenses?
- BridgeBio Pharma (BBIO) reported total costs & expenses of $300.47M in Q1 2026.
- How has BridgeBio Pharma's total costs & expenses changed year-over-year?
- BridgeBio Pharma's total costs & expenses increased by 36.0% year-over-year, from $221.01M to $300.47M.
- What is the long-term trend for BridgeBio Pharma's total costs & expenses?
- Over 4 years (2021 to 2025), BridgeBio Pharma's total costs & expenses has grown at a 12.2% compound annual growth rate (CAGR), from $646.35M to $1.03B.
- What does total costs & expenses mean?
- Total costs and expenses represent the aggregate of all operating and non-operating costs incurred by the company during a reporting period. This includes cost of revenue, R&D, SG&A, and any other operational charges. It is the primary metric for understanding the total burn rate and the overall cost structure of the business.
Ask your AI about BridgeBio Pharma's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude